Q1 revenue growth (10% YoY) was in line, but EBITDA declined 34% YoY (37% below our expectations) on lower gross margin of 50.2% (down 260 bps YoY). Gross margin declined due to (1) price erosion in key partnership products in US; delay in its key approvals